Afstyla Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to diagnosis of hemophilia a, adoption of factor replacement therapy, improved survival rates, availability of recombinant clotting factors, expansion of specialized treatment centers.

The growth in the forecast period can be attributed to growth in prophylactic treatment adoption, rising pediatric diagnosis rates, advancements in recombinant manufacturing, increased homecare utilization, expansion in emerging markets. Major trends in the forecast period include increasing use of recombinant factor viii therapies, growth of prophylactic hemophilia treatment, rising focus on bleed prevention, expansion of home based infusion therapy, improved treatment adherence through dosing flexibility.

The increasing incidence of hemophilia A is expected to drive the growth of the Afstyla market in the coming years. Hemophilia A is a hereditary bleeding disorder caused by a deficiency of clotting factor VIII, which leads to prolonged or excessive bleeding. The rising incidence of hemophilia A is associated with improved diagnostic capabilities, better reporting and awareness, genetic predisposition, and evolving environmental influences. Afstyla supports the management of the growing hemophilia A patient population by offering a long-acting treatment option that enhances treatment adherence, improves quality of life, and supports cost efficiency. For example, in April 2024, according to a report published by the World Federation of Hemophilia, a Canada-based international non-profit organization, the number of newly identified persons with bleeding disorders in PACT countries reached 7,054 in 2023, including 5,188 individuals with hemophilia. The total number of identified patients is projected to increase to 18,832 by 2025. As a result, the increasing incidence of hemophilia A is contributing to the growth of the Afstyla market.

The growing adoption of personalized medicine is also expected to propel the expansion of the Afstyla market. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environmental factors, rather than applying uniform treatment methods. The adoption of personalized medicine has accelerated due to advances in genetic testing, which allow therapies to be tailored to specific patient needs. Afstyla aligns with personalized medicine by enabling individualized factor VIII replacement therapy designed around each patient’s bleeding patterns and treatment requirements. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared with six approvals in 2022. Therefore, the increasing uptake of personalized medicine is supporting the growth of the Afstyla market.

Rising healthcare expenditure is further expected to drive growth in the Afstyla market. Healthcare expenditure includes total spending on medical goods and services, such as personal healthcare, preventive care, and public health initiatives, aimed at improving health outcomes over a given period. Growth in healthcare spending is driven by factors including an aging population, the rising prevalence of chronic diseases, advancements in medical technology, high drug costs, inefficient payment systems, and increased demand for healthcare services. Higher healthcare expenditure supports demand for Afstyla by improving access to advanced therapies and enabling more patients to afford specialized hemophilia care. For example, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared with a growth rate of 0.9% in 2022. In addition, long-term health and social care spending rose by 2.8% in real terms in 2022. Consequently, rising healthcare expenditure is contributing to the growth of the Afstyla market.

Major companies operating in the afstyla market are CSL Behring LLC.

North America was the largest region in the afstyla market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the afstyla market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the afstyla market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the afstyla market by raising costs for imported biologic raw materials, plasma alternatives, and sterile manufacturing inputs. These impacts are more evident in lyophilized formulations requiring complex production and cold-chain logistics. Regions such as north america and europe experience moderate pricing pressure due to regulatory and sourcing dependencies. At the same time, tariffs are driving investments in regional biologics manufacturing facilities. This is improving supply reliability and long-term cost efficiency.

The afstyla market research report is one of a series of new reports that provides afstyla market statistics, including afstyla industry global market size, regional shares, competitors with a afstyla market share, detailed afstyla market segments, market trends and opportunities, and any further data you may need to thrive in the afstyla industry. This afstyla market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Afstyla is a medication used in the management of hemophilia A, a bleeding disorder caused by a deficiency of clotting factor VIII. It is administered intravenously and requires preparation prior to use, helping to prevent or treat bleeding episodes by replacing the missing clotting factor in the bloodstream.

The main formulation types of Afstyla include lyophilized powder and liquid formulations. Lyophilized powder formulations are freeze-dried forms of the medication that are reconstituted with a liquid to create a usable solution and provide enhanced stability and convenience for patients undergoing hemophilia treatment. The clinical indications include prophylactic treatment and on-demand treatment, with distribution through hospitals and clinics as well as retail and specialty pharmacies. The end users include adult, pediatric, and geriatric patients.

The afstyla market consists of sales of recombinant factor VIII vials and injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.